Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues

Publié le 19 Octobre 2018
Mis à jour le 10 septembre 2019

Nucleoside and nucleotide analogues (NUCs) targeting hepatitis B virus are capable of selecting resistant viruses upon long-term administration as monotherapies. To evaluate the prevalence of resistance-associated substitutions (RASs) and fitness-associated substitutions at baseline of NUC therapy and their impact on treatment responses. 232 treatment-naïve patients chronically infected with HBV consecutively referred for the first time to one of French reference centers were included. The nearly full-length HBV reverse transcriptase was sequenced by means of deep sequencing and the sequences were analyzed. RASs were detected in 25% of treatment-naïve patients, generally representing low proportions of the viral quasispecies. All amino acid positions known to be associated with HBV resistance to currently approved NUCs or with increased fitness of resistant variants were affected, except position 80. RASs at positions involved in lamivudine, telbivudine and adefovir resistance were the most frequently detected. All patients with RASs detectable by NGS at baseline who were treatment-eligible and treated with currently recommended drugs achieved a virological response.The presence of preexisting HBV RASs has no impact on the outcome of therapy if potent drugs with a high barrier to resistance are used.

Auteur : Chevaliez Stéphane, Rodriguez Christophe, Poiteau Lila, Soulier Alexandre, Donati Flora, Mercier-Darty Mélanie, Pioche Corinne, Leroy Vincent, Brodard Valérie, Zoulim Fabien, Brouard Cécile, Larsen Christine, Semaille Caroline, Roudot-Thoraval Françoise, Pawlotsky Jean-Michel
Journal of Viral Hepatitis, 2018, p. 1-23